FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (NASDAQ: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced the acceleration of patient enrollment relating to the United States Food and Drug Administration (“FDA”) clinical trials for the Sonablate® 500 (“SB500”), a medical device using high intensity focused ultrasound (“HIFU”) for non-invasive treatment of prostate cancer. The Sonablate® 500 is approved by the FDA as an investigational device for clinical trials in the United States. The increased enrollment pace pertains to the ongoing FDA approved pivotal study for the treatment of prostate cancer. Over 16 patients in the pivotal study have been treated using the SB500 device at two clinical study sites. A third clinical study site will start treatments in June 2007.
